DBV Technologies (DBVT)
DBV Technologies S.A. is a France-based clinical-stage biopharmaceutical company whose common stock is represented in the United States through an ADR listed on NASDAQ. The company focuses on epicutaneous immunotherapy, with a pipeline centered on Viaskin Peanut, which has completed a Phase 3 trial for peanut allergy, and Viaskin Milk, which is in Phase 1/2 testing for IgE-mediated cow’s milk protein allergy and eosinophilic esophagitis. Its earlier-stage research also includes celiac disease, and its Viaskin platform is being developed for potential food allergy treatments. DBV Technologies also collaborates with Nestlé Health Science on MAG1C, a ready-to-use atopy patch test for diagnosing non-IgE-mediated CMPA in infants and toddlers. The company was incorporated in 2002 and is headquartered in Châtillon, France.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-DBVT
|
$12.89
|
-8.6% Downside
|
Fair
|
$40.74
|
188.7% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
July 31, 2026
|
-4.8x
|
5.2x
|
166.4x
|
840.3 M
|
671.1 M
|
0.9%
|
59.6%
|
1.0
|
—
|
97.0%
|
